**Core tip:** Celiac disease (CeD) is a common autoimmune disorder caused by the ingestion of gluten. Its frequency has been increasing, and several factors have been analyzed as possible triggers; among them also food additives should be taken into account. Several nanoparticles are used as food additives or preservatives, and they can interact with the intestine or the immune system, increasing, in theory, the immune response towards gluten. The scope of this review is to analyze the data present in the literature with respect to the pathogenetic mechanisms involved in the development of CeD.

CELIAC DISEASE PATHOGENESIS
===========================

Celiac disease (CeD) is a multifactorial disorder, characterized by the presence of an autoimmune response that mainly involves the small intestine, triggered by the ingestion of gluten from wheat, barley, and rye in genetically predisposed individuals. CeD genetic background is quite complex, and partially still unknown. About 40% of the genetic predisposition relies on genes localized in the human leukocyte antigen (HLA) region, mainly on those encoding for specific class II HLA molecules, namely DQ2.5 and DQ8 heterodimers. The combination of the HLA alleles DQA1\*0501 and DQB1\*0201 generates the HLA-DQ2.5 heterodimer, which is detected in more than 90% of Caucasian CeD patients (either in cis or in trans), whereas the remaining patients carry the HLA-DQ8 heterodimer, encoded by DQA1\*03 (α chain) and DQB1\*0302 (β chain). However, the presence of the DQ2 heterodimer is not sufficient for the development of CeD. In fact, the HLA-DQ2 haplotype is present in 30%-35% of the Caucasian population (in which CeD has a high prevalence), but only 2%-5% of gene carriers develop CeD\[[@B1]\]. Using the Genome Wide Association Study approach, several additional loci have been identified as predisposing to CeD, but in total they account for about 50% of the genetic component.

Although the genetic background is essential for the development of CeD, research has started to focus on the possible environmental factors (apart from gluten) that could trigger the disorder. This could be quite important, since several data suggest that the prevalence of CeD is increasing, and cases are now reported even in populations that were thought to have a negligible prevalence of this disease. A study performed in United Kingdom showed a four-fold increase in CeD incidence rate over a period of 22 years, but regional differences were present\[[@B2]\]. Even if this increased rate could be explained by a different awareness of the problem by physicians, or by the use of an easier serological diagnosis and a casefinding approach, there is still some evidence which suggests that this raise in the prevalence/incidence of the disease is a real phenomenon. Evaluation in a Scottish pediatric population revealed that, in two decades, the incidence of children with nonclassical CeD had increased dramatically (attributable to better diagnosis), but also the number of patients with classical manifestations had quadrupled (thus suggesting a real variation in CeD frequency)\[[@B3]\]. Moreover, similar data have been observed in Finland as well as in the United States\[[@B4]-[@B6]\].

To identify the possible additional environmental causes it is necessary to dissect the various steps involved in CeD pathogenesis. The ingested gluten undergoes digestion, which generates several small peptides, including the 33 mer peptide (residues 57 to 89 of α-gliadin), a celiac "superantigen" able to stimulate T cells\[[@B7]\], or the 31-43 peptide (from residues 31 to 43 of α-gliadin), which can have a toxic effect on intestinal mucosa\[[@B8]\]. However, in order to trigger the autoimmune response these peptides need to cross the gastrointestinal barrier and reach the lamina propria. This passage can take place using two different routes, namely the transcellular and the paracellular one. The first is a vesicle-mediated passage which involves endocytosis on the luminal side of enterocytes, followed by transcytosis and release on the basolateral side. Thus, in theory, substances which are able to make the gluten peptides more prone to be captured on the apical side and transported could play a role in the pathogenesis of CeD. Conversely, paracellular transport depends on tight junctions (TJ) and the correct expression/interaction of the proteins that maintain junction functionality. Therefore, agents able to induce inflammation and/or cytokine release could cause the rearrangement of proteins such as ZO-1 or occludin, causing a loss of function of TJ and, in turn, an increased paracellular passage of lumen substances, such as gluten peptides.

Once gluten peptides have crossed the intestinal barrier, they are further processed in the submucosa; due to their high content in glutamine, proline and hydrophobic amino acid residues, these peptides are excellent substrates for transglutaminase 2 (TG2) which deamidates them. This processing increases negative charges, allowing the gluten peptides to bind more strongly to HLA-DQ2 (or HLA-DQ8). Better antigen presentation results in CD4+ Th1 T-cell activation that, in turn, will cause activation of intraepithelial lymphocytes, crypt hyperplasia and villus atrophy, as well as B cell stimulation and the production of auto-antibodies directed against deamidated gliadin peptides and TG2 (Figure [1A](#F1){ref-type="fig"}).

![Role of Food additives in the pathogenesis of celiac disease. A: The pathogenesis of celiac disease involves the digestion of gluten in the gut lumen, the increased passage of gluten peptides through the intestinal epithelium, the deamination by the tissue transglutaminase 2 and the uptake by antigen-presenting cells. Once the gluten peptides are presented within the HLA class II molecule they activate CD4+ T cells, which in turn trigger the destruction of the tissue by CD8+ T cells and the production of autoantibodies by B cells. The increase amount of gluten or bacterial transglutaminase used as additive could increase this process; B: Metallic nanoparticles could affect both gluten passage through the epithelium (paracellularly or intracellularly) or the presentation of the antigen by dendritic bells. Moreover they can alter the microbiota, influencing gluten processing and/or immune response.](WJCC-7-917-g001){#F1}

Given these data, food additives could have a role in triggering the development of CeD if they are able to alter the gastrointestinal barrier, antigen presentation or the activation of the immune system. Although there are currently few experimental published data that specifically address the interaction between food additives and CeD, there are at least three possible categories that should be analyzed, namely transglutaminase, gluten nanoparticles and metallic nanoparticles.

USE OF TRANSGLUTAMINASE IN FOOD PREPARATION
===========================================

The use of transglutaminase in food processing belongs to the various techniques that industries in the field currently use to modify the proteins present in aliments. Microbial transglutaminases (mTGs), like human ones, catalyzes acyl transfer, deamidation and crosslinking between glutamine (acyl donor) and lysine (acceptor). These reactions can profoundly modify a large amount of proteins constituting food matrices and this, in turn, can improve several food properties such as texture and stability; more interestingly, these changes can take place without affecting other food characteristics like taste or nutritional value. For these reasons, the possible ingestion of microbial tranglutaminases, due to its use in food processing, has been recognized as safe by Food and Drug Administration\[[@B9]\].

Currently mTGs are is used in several processed foods since, among others, their use increases the water retention capacity of proteins, fact that could help to increase the juiciness of products such as meat, or emulsion properties that are important in food characterized by creamy texture (*e.g*., yogurt)\[[@B10]\]. Moreover, bacterial transglutaminase treatment has also been applied to cereal proteins (including wheat protein); its use can improve stability, elasticity and water retention of the dough, and for this reason it has also been employed in the preparation of gluten-free food\[[@B11]-[@B12]\].

Due to the pivotal role of transglutaminase in the pathogenesis of CeD, its use in food preparation has raised some concern. Transglutaminases can act on gluten peptides, making them more immunogenic, but it must also be remembered that TG2 is itself an autoantigen, and the ingestion of mTGs could also generate an autoimmune response through a molecular mimicry mechanism. The comparison of the primary and tertiary structure of a commonly used mTGs with TG2 reveals little homology, although both are able to bind gluten peptides using similar aminoacids\[[@B13]\]. Moreover, mTGs can deamidate gluten peptides, making them more immunogenic, as assessed in an *in vitro* system that employed gluten-specific T cells isolated from the duodenum of celiac patients\[[@B14]\].

Few papers have tried to assess the possible correlation between the use of bacterial transglutaminase and CeD, but most of them are only based on peptide-patients' antibody interaction. An initial investigation performed using sera from nine celiac patients suggested that treatment of wheat with mTGs increases the IgA-based reactivity, and to a lesser degree when mTGs were used to treat gluten-free bread\[[@B15]\]. Matthias et al\[[@B16]\] evaluated the presence of antibodies directed against either human or bacterial transglutaminase (alone or bound to gluten peptides) in pediatric patients with or without CeD. In the serum of CeD patients, they could detect antibodies against mTGs, although prevalently IgG rather than IgA (as commonly observed against TG2), whereas they were not present in controls. The authors also found a correlation between serum levels of antibodies against mTG-peptides and TG2-peptides, as well as between these serum titer and intestinal damage, and they suggested a causal role of this food supplement in the development of CeD. Different results were observed by Ruh et al\[[@B17]\], who extracted gliadin from pasta treated or untreated with mTGs and employed it to assess possible reactivity with circulating antibodies present in CeD patients. The authors detected a huge variation among patients, but no difference in reactivity between the two types of gliadin. These results were also confirmed by Heil et al\[[@B18]\].

On the contrary, in theory, the use of mTGs could also be useful to decrease the immunogenicity of gluten, but in order to do so the enzyme has to be used in association with acyl-acceptor molecules such as lysine\[[@B19]\]. This pre-treatment of gluten could in fact block the aminoacids that are the usual target of TG2, thus preventing the modifications that increase the affinity of gluten peptides for the DQ2 molecule\[[@B13],[@B20]\]. Moreover, experiments performed *ex vivo* on duodenal biopsies of CeD patients showed that the modification of gluten by mTGs with L-lysine prevented pro-inflammatory cytokine production\[[@B21],[@B22]\]. Gluten transamidation by mTGs could thus be used to produce flour of bread with less immunoactive gluten peptides\[[@B23],[@B24]\], but there are still some issues that need to be clarified, due to the affinity of mTGs for the aminoacids usually targeted by TG2 and to the possibility that TG2 overcomes the modification induced by mTGs.

GLUTEN-BASED NANOPARTICLES
==========================

Gluten-based nanoparticles have been mainly developed as a tool for drug delivery, and have been tested in particular for hydrophobic drugs\[[@B25]\]. However, there is another use that could be potentially problematic, *i.e*., the development of coating matrices for paper and cardboard used for food packaging. Plant-derived proteins have good film-forming properties, are biodegradable, and can be produced with moderate costs, facts that make them suitable for coating food containers. Some authors have also combined gluten with nanocellulose and titanium dioxide in order to obtain nanocomposites able to increase the resistance of paper. These na-nocomposites also have an antibacterial activity, a quality that might be very attractive for food-preserving packages\[[@B26]\]. As will be mentioned later, the issue regarding these nanomaterials is that data about the possible release of nanoparticles in food are needed.

METALLIC NANOPARTICLES
======================

Nowadays several nanoparticles (NPs) are intentionally added to food, beverages and their packages\[[@B27]\], mainly to preserve aliments\[[@B28],[@B29]\] or to improve their organoleptic properties (such as taste, consistency and appearance). Consequently, in recent years, an increase of toxicological studies on food nanoparticles has been registered. Although NP can enter the body through several routes, according to the Nanotechnology Consumer Product Inventory (CPI) enlisted in 2014, one of the major NP points of entry is the gastrointestinal system\[[@B30]\]. They also reported that nanomaterials are particularly present in commercial food or food-related products under the form of metallic nanoparticles (mNP), of which Ag (E174), TiO2 (E171), ZnO, Au (E175) and SiO2 (E551) NPs are the most popular. Briefly, AgNPs are particularly used as antimicrobial agent in aliments/beverages, their packages and in agriculture\[[@B29]\]; ZnONPs are also used as strong antibacterial agents, but they can also be used as a dietary supplement; E171 is used as a whitening agent in pharmaceutical, dairy and pastry products; AuNP is mostly present as a contaminant from dental restoration material or agriculture-derived products (such as seeds)\[[@B31],[@B32]\]; SiO2NP is employed to improve the organoleptic properties of food and its nutritional values.

In order to evaluate the possible effects of ingested NP, there are several factors that should be taken into account: (A) NP dimensions: several studies reported as the size of food mNP might alter their uptake from intestinal cells\[[@B33]-[@B35]\]. The smaller the mNP, the faster and easier will be its passage through the mucous layer and its passage into the mucosa either by transcellular or paracellular transport; (B) Core material: it could determine whether NPs remain intact or partially digested by the intestinal fluids. An important concern is in fact the propensity of NPs to be dissolved and release heavy metals, which in turn affects NP toxicity. In this sense, AgNP, ZnONP and CuONP are regarded as the most dangerous food nanoparticles\[[@B36],[@B37]\]. NP core composition also determines the chemical reactivity, substance adsorption on NP surface, and possibly the epithelial translocation route\[[@B38],[@B39]\]; (C) Aggregation/agglomeration state: NPs can arrive into the gut as single entities or in clusters (agglomerates or aggregates\[[@B40]\]). This feature depends on the NP composition, but also on the physiochemical properties of the environment. It has been reported that the degree of aggregation/agglomeration of SiO2-, Ag- and aluminium-NPs can change in artificial mouth, gastric and intestinal conditions\[[@B41]-[@B43]\]. At the same time, this factor also affects NP uptake and toxicity, as demonstrated by McCracken et al\[[@B44]\] and Albanese et al\[[@B45]\]; (D) Gastrointestinal environment and food: Physiochemical features of food, beverages, and the gut are important factors that influence NP stability, size, surface composition and aggregation/agglomeration state\[[@B41],[@B43],[@B44],[@B46],[@B47]\]. Wang et al\[[@B48]\] and Cao et al\[[@B49]\] demonstrated a higher oxidative stress-related toxicity exerted by ZnONP when associated with Vitamin C and palmitic oil, respectively; on the contrary the presence of flavonoids or quercetin seems to protect against AgNP toxicity\[[@B50],[@B51]\].

Although the daily consumption of metallic NPs is usually thought to be trivial, this is not the case, in particular if TiO2 is taken into account. Early studies suggested that average daily human consumption of TiO2 was 5.4 mg per person\[[@B52]\], 0.035 mg/kg of body weight (b.w.)/d\[[@B53]\] and 5 mg/person\[[@B54]\]. More recent papers, however, estimated a daily intake of 1--2 mg TiO2/kg b.w. for United States children under 10 years of age, and 0.2-0.7mg TiO2/kg b.w. for other United States consumers\[[@B55]\], whereas EFSA data reported a range between 0.2 and 0.4 mg/kg b.w. in infants and the elderly, and 5.5-10.4 mg/kg b.w. in children, depending on the exposure\[[@B56]\]. Although these data should be corrected for the percentage on TiO2 NPs present in the E171, it must be noted that these quantities are not far from the estimates for the lowest observed adverse effect level (LOAEL) of 5 mg/kg body weight/d derived for nano‐ TiO2 by the European Commission's Scientific Committee on Consumer Safety\[[@B57]\].

The effects of mNP that could have a role in CeD development involve three different aspects, namely the impairment of the intestinal barrier, the interaction with the immune system and the possible effect on microbiota (Figure [1B](#F1){ref-type="fig"}).

Intestinal barrier impairment
-----------------------------

The first layer of the small intestinal barrier is a very thin (approximately 20 micron) layer of mucus, composed of mucin glycoproteins and antimicrobial agents such as secretory IgA. The second layer is a continuous and tight epithelium, composed of several specialized cells: at the bottom of the crypts reside stem and Paneth cells, whereas enterocytes, goblet and enteroendocrine cells are mainly in the villi. What makes the epithelium a selective barrier is the presence of highly dynamic intercellular junctions, adherent junctions (AJ) and TJ being the most representative. AJ are composed of transmembrane proteins cadherine, which are connected between them extracellularly, and with the catenin proteins in the cells. Catenins are in turn linked to the acti-myosin complex. TJ are formed by occludins, claudins and JAM-A proteins that interact with zonula occludens proteins and catenins in the intracellular space. Therefore AJ, TJ and actin cytoskeleton form a complex that can regulate the permeability (paracellular route) of the intestinal barrier, following intracellular or extracellular signals.

A growing number of diseases have recently been associated with intestinal barrier alterations, particularly related to TJ dysfunction. This finding can be easily explained: gastrointestinal barrier permeability alterations can increase the cut-off of molecules passing into the submucosa. In physiological conditions, only small molecules with a molecular weight of about 600da can pass the barrier, but these alterations result in the passage of immunogenic molecules, the activation of the immune system and the establishment of an inflammatory state. Since inflammatory mediators are also known to affect the intestinal barrier, a mild inflammatory status could eventually lead to a stronger disruption of the barrier itself\[[@B58]\]. Particularly important in this sense is the association of a leaky barrier with inflammatory bowel diseases (IBD) and several autoimmune diseases, such as CeD\[[@B58]-[@B60]\]. To develop CeD, gluten peptides have to pass into the submucosa. Therefore, any factors which are able to alter the intestinal barrier permeability, allowing an higher passage of these peptides into the submucosa, may increase the number of predisposed subjects developing the disease.

In 2015 Lerner and Matthias\[[@B61]\] observed that the increase in the incidence of autoimmune diseases (considering also CeD among others) paralleled with the growing use of food additive in the industry. They therefore postulated that the permeability alterations induced by food additives could be associated with the increment in incidence of autoimmune diseases. Although the author did not refer directly to the mNP, several studies have been performed on their impact on the GI barrier. Results showed that mNP can alter the intestinal permeability both directly, by altering the TJ or inducing epithelial cell death\[[@B34],[@B62]-[@B64]\], or indirectly, by inducing inflammation or oxidative stress that in turn can impair TJ and permeability\[[@B58],[@B65]\]. In this context, the work of Ruiz et al\[[@B66]\] is interesting. It looked at the impact of TiO2NP both *in vivo* (mice with DSS-induced ulcerative colitis) and *in vitro* (intestinal epithelial cells and macrophages). TiO2NP oral administration worsened the already established colitis through inflammasome activation. Also, *in vitro* stimulations induced IL-1β and IL18 increment, as well as higher epithelial permeability driven by the activation of the inflammasome pathway. These results clearly associate the consumption of mNP with an increase of the intestinal permeability, but only when there is a pre-existent tendency to develop it.

However, even if the studied mNP does not induce permeability alteration, it has to be considered that the mNPs may absorb the protein itself on its surface and therefore behave as a "Trojan horse", increasing the amount of immunogenic molecules that arrive into the submucosa\[[@B67],[@B68]\]. Thus, in the case of CeD, food NPs could bind gliadin peptides and help them to cross the intestinal barrier, probably using the endocytotic pathway. Several studies are needed to test this hypothesis, since no data are currently available on this topic. Moreover, it will be necessary to take into account the interaction with other food components\[[@B69],[@B70]\], and with the intestinal mucus\[[@B71]\], since both components can alter NPs uptake by enterocytes.

On the other hand, it must be underlined that NPs can play a role in the pathogenesis of other gastroenterological disorders, and concerns have also been raised for several evidences that linked NPs, particularly the whitening agent E171(TiO2NP), to IBD development\[[@B66],[@B72],[@B73]\].

mNPs and the immune system
--------------------------

mNPs can interact with cells involved in innate and adaptive immune response in several organs, altering cytokine production, activation of cell surface receptors and/or cell maturation (including the ability of cells to present antigens)\[[@B74]-[@B77]\]. Nanoparticles can be recognized as foreign materials and eliminated by the immune system, but they can also trigger an excessive activation of immune responses. This could be useful should NP be used as an adjuvant in vaccinations, but could be detrimental in case of autoimmune disorders. In particular, the binding of gliadin peptides to food NP could represent a way by which these specific antigens can be taken up in great quantity by antigen presenting cells, thus increasing the activation of the autoimmunity process. Several studies have been performed on macrophage-like cell lines to assess the effect of metallic NPs, analyzing the cytotoxicity as well as differences in cytokines production; AgNPs were able to increase the production of IL-8\[[@B78],[@B79]\], which also depended on NP size\[[@B78]\] whereas TiO2 NPs increased the secretion of TNF-α and IL-6\[[@B80]\]. Interestingly, Au-NPs induced an alteration in phagocytosis without variation in cytotoxicity or cytokine gene expression\[[@B81]\], whereas a similar effect by TiO2 NPs was associated with an inflammatory response\[[@B82]\]. Transcription profiling on a macrophage cell line treated with different NPs revealed a particular expression pattern, thus suggesting that each metallic NP can trigger a specific response, also depending on the chemical characteristics of the nanoparticle itself\[[@B83]\]. Silver NPs have been demonstrated to be able to interact with human monocytes, increasing the production and release of IL-1β, even after the exposure to very low concentrations\[[@B84]\]. Ag-NP were also able to cause superoxide production, as well as the formation of inflammasome. Metallic NPs also altered the expression of adhesion molecules and chemokine receptor type 4 on the surface of human peripheral lymphocytes\[[@B85]\]; interestingly, these effects were independent from any sign of cytotoxicity, suggesting that the response to NP exposure can be more subtle and mainly related to gene expression variations. However, NPs can also interact with cells involved in adaptive immune response, and *in vitro* data showed that TiO2 NPs can induce maturation of dendritic cells through the activation of Nf-kB pathway\[[@B86]\], a process which is essential for antigen presentation to T helper cells. Again, this process could be important in CeD, since antigen presentation by dendritic cells represents an essential step for the activation of the autoimmune response.

Nanoparticles and microbiota
----------------------------

Microbiota plays an important role in maintaining the homeostasis of a healthy gut. Alterations in microbiota composition have been reported both in pediatric as well as adult CeD patients if compared to controls\[[@B87]-[@B89]\], although it is currently still unknown whether these changes are causative of the disease or a consequence of mucosal alterations.

However, microbiota can be altered by exposure to dietary mNP. *In vitro* experiments performed on a colon-like microbial community showed that exposure to small quantities of E171 (comparable to the amount present in two pieces of chewing gum) was sufficient to alter the phylogenetic composition\[[@B90]\]. Significant changes in the phyla were also observed in mice treated for 28 d with TiO2NP, with variations induced by both forms of TiO2NP, namely rutilium and anatase\[[@B91]\].

As already mentioned, silver nanoparticles are employed as antibacterial agents, and thus it should be expected that they can alter the microbiota composition. In fact, in mice exposed to increasing doses of AgNP for 28 d, a disturbed bacterial evenness (αdiversity) and populations (β-diversity) was detected by Next Generation Sequencing. This effect was also dose-dependent. Ag NP increased the ratio between Firmicutes (F) and Bacteroidetes (B) phyla, results similar to those observed in presence of inflammation\[[@B92]\]. Variation in microbiota composition were also observed by another group, although results were different regarding the phyla, possibly due to the different experimental design (rats treated for 14 d)\[[@B93]\].

Last but not least, it must be emphasized that within our gut there is also a viral component that interacts with the microbiota and the intestinal mucosa. Although studies evaluating the possible effect of food NP on this component are scanty, initial data obtained *in vitro* suggest that Ag-NP can alter the abundance of several viral species\[[@B94]\]. Since these species can be hosted by different categories of bacteria (commensal or pathogenic), changes in intestinal viriome can, in turn, cause alteration in the microbiota itself.

CONCLUSIONS
===========

Food additives could play an important role in the pathogenesis of CeD, either altering gliadin peptides properties or interacting with the intestinal environment, at the barrier level or with the immune system. Moreover, the increasing use of prepared food and, in turn, the augmented ingestion of NPs, could be an additional factor in triggering the development of CeD in genetically predisposed individuals. For this reason, *in vitro* and *in vivo* studies to evaluate these possible interactions are needed.
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